GlassScriptPhysician profile
Cecilio Hernandez
NPI 1336298892
$2,708.54
in general payments reported to CMS, 2019-2025
39 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $283 · 2021: $269 · 2022: $538 · 2023: $133 · 2024: $435 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $492.28 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $219.01 | 2019-2025 | Ultomiris |
| Abbvie INC. | $168.68 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $164.73 | 2019-2022 | |
| Horizon Therapeutics Plc | $145.27 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $118.50 | 2022-2025 | |
| Vifor Pharma, INC. | $118.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $107.28 | 2019-2024 | Lokelma |
| Sunovion Pharmaceuticals INC. | $88.25 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $85.03 | 2022 | |
| Amgen INC. | $84.76 | 2019-2025 | Krystexxa |
| Argenx US, INC. | $73.94 | 2025 | Vyvgart Hytrulo |
| Genzyme Corporation | $68.08 | 2019-2020 | |
| Outset Medical INC | $63.45 | 2023 | |
| Mallinckrodt Enterprises LLC | $62.91 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $54.32 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $53.50 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.03 | 2024-2025 | Jardiance |
| Ucb, INC. | $43.90 | 2024-2025 | Nayzilam, Briviact |
| Lundbeck LLC | $43.52 | 2019 | |
| Merz Pharmaceuticals, LLC | $35.01 | 2024 | Inbrija |
| Neurocrine Biosciences, INC. | $34.11 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $33.48 | 2025 | Hyqvia |
| Tg Therapeutics, INC. | $29.19 | 2025 | |
| Scpharmaceuticals INC. | $27.78 | 2025 | |
| Emd Serono, INC. | $22.77 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.40 | 2020 | |
| Eisai INC. | $22.33 | 2024 | |
| Grifols USA, LLC | $21.95 | 2025 | Gamunex-C |
| Daiichi Sankyo INC. | $21.01 | 2020 | |
| Akebia Therapeutics INC | $20.53 | 2019 | |
| Genentech USA, INC. | $19.09 | 2025 | Ocrevus Zunovo |
| Arbor Pharmaceuticals, INC. | $17.99 | 2019 | |
| Kyowa Kirin, INC. | $17.73 | 2020 | |
| Tanabe Pharma America, INC. | $15.02 | 2024 | |
| C2n Diagnostics, LLC | $14.74 | 2025 | Precivityad2 |
| Shire North American Group INC | $14.04 | 2019 | |
| Medtronic Vascular, INC. | $13.67 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecilio Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.